IRS Guidance Lets Grant-Funded Businesses Expense R&E Costs Without CAMT Penalties (2022–2024)

Hook: A Major Tax Relief for Research-Driven Organizations

If your business or nonprofit has received federal funding for research and development (R&D), the IRS just delivered a welcome piece of news. Under new guidance (Rev. Proc. 2025-28), organizations can fully expense unamortized domestic research and experimentation (R&E) expenditures from 2022–2024 without facing Corporate Alternative Minimum Tax (CAMT) penalties through the end of 2024. Better yet, starting in 2025, you can choose to deduct R&E costs as incurred—restoring a valuable cash flow advantage for innovation-focused grant recipients.

Context: Why This IRS Change Matters Now

For years, Section 174 of the Internal Revenue Code let businesses immediately deduct their qualified research expenditures. That changed with 2017’s Tax Cuts and Jobs Act (TCJA), which required R&E costs to be amortized over five years. The result? Many research-intensive organizations, including those using federal grants (e.g., NIH, NSF, SBIR), saw restricted deductions and higher taxable income—even though the expenses were already incurred.

Congress attempted to reverse this with the OBBBA (legislation that, among other things, restored immediate expensing for domestic R&E costs), and the IRS guidance implements the legislative fix. The new rules affect how researchers, small businesses, and grant-funded nonprofits account for past and future R&D costs—especially as they intersect with indirect rates and cost matching for federal grants.

Why is this timing critical? Taxpayers filing their 2025 returns (due September 15, 2026, for calendar-year corporations) now have options for deducting accumulated R&E costs—potentially resulting in sizable cash flow improvements just as we face an uncertain funding environment.

Impact: What It Means for Research Organizations and Grant Recipients

1. Improved Cash Flow & Budgeting:

• Deductions for prior years’ R&E spending (2022–2024), which were previously locked up in five-year amortization schedules, can now be recognized immediately in 2025 or split between 2025 and 2026. This means lower taxable income and a possible influx of cash that can be reinvested in ongoing projects or used as match funding for grants.

2. No CAMT Penalties Through 2024:

• The IRS clarified that these accelerated deductions won’t trigger additional CAMT liability for tax years through 2024. (CAMT is a new minimum tax calculation for large corporations, but this safe harbor is a major relief for high-R&D organizations.)

3. Greater Flexibility Going Forward:

• For tax years starting after December 31, 2024, you can choose either to fully deduct new R&E costs in the year they’re paid or to amortize them over at least 60 months. The prior forced five-year amortization is gone—potentially lowering barriers to launching new research initiatives, especially in partnership with federal agencies.

4. Consistency with Federal Grant Policies:

• Many grants (NSF, NIH, SBIR, etc.) require accurate reporting of research expenditures and alignment between tax returns and indirect cost rates. Immediate expensing may simplify reporting and indirect cost negotiations, but organizations still need to coordinate with group entities, as R&D credit calculations must be treated consistently.

Action: Steps Research and Grant-Funded Organizations Should Take Now

1. Review Past R&E Costs (2022–2024): Identify unamortized domestic R&E expenses on your books. Work with accountants to assess the impact of accelerating deductions all at once in 2025 versus spreading them over 2025 and 2026.

2. Evaluate Tax Elections and Method Changes: The new rules are automatic for the next two years, but you must formally select your method (full deduction or amortization) and file the required accounting method change. Don’t wait until the last minute—these decisions affect both your tax liability and your grant budgeting.

3. Coordinate with Grant Managers and Auditors: Ensure the expenses you claim for grants align with your tax filings to avoid compliance headaches during audits. NSF and NIH awards, for example, require clear documentation of research costs.

4. File On Time: The IRS guidance applies to 2025 tax returns, typically due September 15, 2026, for most organizations. Filing on time ensures you benefit from these elections and avoid defaulting to less favorable amortization rules.

Outlook: What to Watch For Next

While this guidance restores a crucial incentive for U.S. R&D investment, ongoing compliance is key. Monitor for:

• Additional guidance from the IRS or Treasury clarifying indirect cost impacts for nonprofits and educational institutions.
• Any further legislative changes that might affect Section 174 or R&D credits.
• Industry best practices as organizations implement new expensing methods in 2025.

For a detailed look at the IRS guidance, see summaries from CBIZ and BDO.

Need to streamline your grant and R&D expense reporting? Granted AI can help you keep funding applications aligned with the latest tax and compliance rules.